Julio Gay-Ger – President & General Manager, Lilly China
Julio Gay-Ger, an industry and Eli Lilly veteran, shares how he is leveraging on his 23 years of experience managing Lilly affiliates in LATAM to deliver on Lilly’s objective to…
Under the China Association of Enterprises with Foreign Investment (CAEFI), the R&D-based Pharmaceutical Association Committee (RDPAC) is a non-profit organization made up of 41 member companies with pharmaceutical R&D capability.
Statistics show that over RMB20 billion was invested by 40 RDPAC members during the 11th Five Years Plan. And nearly one-third of the investment was allocated in the construction of R&D centre. 70% of RDPAC members have established manufacturing facilities in China summing up to 49 in total so far, and 31 R&D centres were established by 17 companies.
Holding the idea of “Healthier China through Innovation”, RDPAC committed to being a valued partner in delivering the “Healthy China 2020” goal to improve the health and quality of life of people in China：
● Providing our high-quality/ innovative healthcare products and services in a socially responsible and commercially viable manner;
● Committed to securing patients timely access to innovative & high quality drugs;
● Achieving highest standard of integrity for ethical research and business practice;
● Contributing to the growth of the biopharmaceutical sector in China;
● Supporting the development of a sustainable healthcare system in China.
RDPAC is a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).
Contact
Rm 506, Office Bldg 1, Landmark Tower, No.8 North Dongsanhuan Rd, Chaoyang District, Beijing 100004, P.R.China
Tel: +86 10 6590 7696
info@rdpac.org
Julio Gay-Ger, an industry and Eli Lilly veteran, shares how he is leveraging on his 23 years of experience managing Lilly affiliates in LATAM to deliver on Lilly’s objective to…
Yan Hao, chairman and CEO of EPS Group shares the company’s journey to become Japan’s largest and most comprehensive provider of optimal outsourced solutions to the healthcare industry through its…
Asgar Rangoonwala, president of Xian Janssen, Janssen’s Chinese affiliate, shares the key milestones for the affiliate in the past two years, how Janssen is investing in bringing new innovations to…
Dr Jun Bao, appointed president and CEO of Impact Therapeutics in October 2018, shares his aspirations for Impact to be a leader in synthetic lethality in oncology; the importance of…
Click here to register and download PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: China. From the world’s ninth largest pharma market in 2007 to its second-biggest merely 12…
Lorena Di Carlo, a Lundbeck veteran, shares her first impressions of her six months as general manager of Lundbeck China, the strategic significance of China to Lundbeck’s global organization, the…
China’s unbridled growth has spurred a vast number of overseas Chinese to return home to seek new opportunities in their transformed homeland. Affectionately known as ‘sea turtles’ because the Chinese…
Dr John Yu, co-founder and CEO of CGeneTech, shares the exciting story behind the company’s establishment in 2010; its balanced philosophy on new drug development and the progress of their…
Fendy Yanhui Feng, vice president of Eisai Co., Ltd. and president of Eisai China Holdings Ltd. and Eisai China Inc., shares the significant improvements she has made to Eisai’s China…
Research has established that proper nutrition during hospitalization helps to reduce the number of infections, the duration of treatment needed for recovery, and reduce the readmission rateCecily Gu discusses her…
Samantha Du, Chairman and CEO of Zai Lab, the flagship China biotech company, shares her inspirational story of being one of the pioneers to forge a path for Chinese biopharma…
Lydia Guo, Grace Zhao and Mendy Zhang of executive search firm Egon Zehnder outline some of the latest trends affecting the Chinese pharma sector and what they look for in…
See our Cookie Privacy Policy Here
